Preliminary studies of epidemiological, clinical, laboratory, and neuroimaging findings revealed no differences between PMM2-CDG patients with SLE and those without, and in terms of the genotype, all the pathogenic variants were distributed among both groups (5, 8–12). This evidence concerns the gene PMM2 and systemic lupus erythematosus.